CHARLESTON, S.C., May 3, 2011 (GLOBE NEWSWIRE) -- Revolutions Medical Corporation ("Revolutions Medical" or the "Company") (OTCQB:RMCP) announces today that the Company has filed a provisional patent application in order to expand its current proprietary vacuum technology to now include pre-filled safety syringes. The new patent application will strengthen the Company's overall patent coverage related to vacuum safety syringe technology and will allow the Company to address a growing market segment currently experiencing significant attention by pharmaceutical companies. Foley and Lardner, LLP, Revolutions Medical's patent attorneys, expect this new provisional patent application to result in a family of patent filings on this new vacuum technology. One of the many new design features includes the needle being safely retracted within the syringe body during manufacturing, eliminating the need for a needle safety cap.
"The Company continues to stay true to its mission and looks forward to being able to share its new pre-filled safety syringe designs with potential pharmaceutical strategic partners. There are currently almost 50 drugs, including insulin, that are now being delivered in other pre-filled syringes. I believe that our new pre-filled vacuum safety syringe designs have a number of advantages over the current competition," stated Ron Wheet, Chief Executive Officer and Chairman of Revolutions Medical.
Revolutions Medical currently owns two U.S. patents on its proprietary vacuum syringe technology as well as one U.S. patent on a vacuum phlebotomy or blood drawing device. The Company also owns seven international patent applications on its proprietary vacuum technology that are currently pending in China, Japan, Mexico, Australia, Taiwan, Canada, and Europe. The Company plans to file international patent protections on its new provisional patent application that was recently filed with the U.S. Patent and Trademark office for its new pre-filled vacuum design.
About Revolutions Medical Corporation
Revolutions Medical is a safety medical device and software application company. Its products include the RevVac™ Safety Syringe (FDA cleared), safety blood drawing device, the RevColor™, RevDisplay™ and Rev3D™ software tools that are compatible with standard MRIs and standard Picture Archiving Computer Systems (PACS). The Company also has an exclusive license to a Breast Biopsy System (BBS), preliminary called RevTrack (FDA cleared).
For additional information, please visit Revolutions Medical corporate website:
To be added to the Revolutions Medical investor email list, please email:
firstname.lastname@example.org with RMCP in the subject line.
Become a RevMed fan and follow the Company on Facebook – visit:
The information contained herein includes forward-looking statements. These statements relate to future events or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
CONTACT: Revolutions Medical Corporation Investor and Corporate Relations Gregory S. Lowe Acorn Management Partners President / Partner 678-368-4013